Genetic Technologies Limited
GNTLFOTCHealthcare● Active
$1.00
+$0.00(+0.00%)
Market Cap$1.3B
P/E Ratio—
52W High$1
52W Low$1
Genetic Technologies Limited (GNTLF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GNTLF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2025Report Date: Jun 2, 2025EPS Actual
-$0.02
Revenue
$0.00B
Fiscal Period
Q2 FY2025
FY ends December
Report Date
Jun 2, 2025
After Market Close
GNTLF reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 27, 2026 | — | — | — | — | — | — |
| ◌ Q3 FY2026 | Aug 27, 2026 | — | — | — | — | — | — |
| ◌ Q3 FY2025 | Aug 4, 2025 | — | — | — | — | — | — |
| — Q2 FY2025 | Jun 2, 2025 | — | -$0.02 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 29, 2024 | — | -$0.03 | — | $0.00B | $0.00B | +6.7% |
| — Q2 FY2024 | Apr 29, 2024 | — | -$0.04 | — | $0.00B | $0.00B | -5.7% |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.04 | — | $0.00B | $0.00B | -38.1% |
| — Q4 FY2022 | Dec 31, 2022 | — | -$0.04 | — | $0.00B | $0.00B | -42.9% |
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 27, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 4, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
Jun 2, 2025
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 29, 2024
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 29, 2024
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Dec 31, 2022
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2025 | Jun 2, 2025 | — | $1.00 | $1.00 | +0.00% |
| — Q3 FY2024 | Aug 29, 2024 | — | $0.07 | $0.07 | +0.00% |
| — Q2 FY2024 | Apr 29, 2024 | — | $0.07 | $0.07 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.15 | $0.15 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.40 | $0.40 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $0.25 | $0.25 | +0.00% |
| — Q4 FY2021 | Dec 31, 2021 | — | $0.20 | $0.20 | +0.00% |
| — Q2 FY2021 | Jun 30, 2021 | — | $0.30 | $0.30 | +0.00% |
Q2 FY2025+0.00%
Report Date
Jun 2, 2025
EPS Beat/Miss
—
Price Before
$1.00
Price After
$1.00
Q3 FY2024+0.00%
Report Date
Aug 29, 2024
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.07
Q2 FY2024+0.00%
Report Date
Apr 29, 2024
EPS Beat/Miss
—
Price Before
$0.07
Price After
$0.07
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.15
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.40
Price After
$0.40
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$0.25
Price After
$0.25
Q4 FY2021+0.00%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$0.20
Price After
$0.20
Q2 FY2021+0.00%
Report Date
Jun 30, 2021
EPS Beat/Miss
—
Price Before
$0.30
Price After
$0.30
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GNTLF ends December
Genetic Technologies Limited (GNTLF) most recently reported earnings on June 2, 2025 for Q2 FY2025, posting EPS of $-0.02 (in line with the analyst consensus of —). The next GNTLF earnings date is expected around September 1, 2026.
Each quarter, investors track GNTLF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GNTLF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GNTLF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GNTLF earnings · 4 questionsGenetic Technologies Limited's next earnings report is expected around September 1, 2026. GNTLF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GNTLF historically reports after market close (AMC).
GNTLF earnings datewhen is GNTLF earningsGNTLF next earnings datewhen does GNTLF report earningsGNTLF earnings calendar
▸ Source: FMP · Genetic Technologies Limited SEC filings · US GAAP · Genetic Technologies Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026